Glycan masking of a non-neutralising epitope enhances neutralising antibodies targeting the RBD of SARS-CoV-2 and its variants.

Autor: Carnell GW; Lab of Viral Zoonotics, Department of Veterinary Medicine, University of Cambridge, Cambridge, United Kingdom., Billmeier M; Institute of Medical Microbiology & Hygiene, Molecular Microbiology (Virology), University of Regensburg, Regensburg, Germany., Vishwanath S; Lab of Viral Zoonotics, Department of Veterinary Medicine, University of Cambridge, Cambridge, United Kingdom., Suau Sans M; Lab of Viral Zoonotics, Department of Veterinary Medicine, University of Cambridge, Cambridge, United Kingdom., Wein H; Institute of Medical Microbiology & Hygiene, Molecular Microbiology (Virology), University of Regensburg, Regensburg, Germany., George CL; Lab of Viral Zoonotics, Department of Veterinary Medicine, University of Cambridge, Cambridge, United Kingdom., Neckermann P; Institute of Medical Microbiology & Hygiene, Molecular Microbiology (Virology), University of Regensburg, Regensburg, Germany., Del Rosario JMM; DIOSynVax, Ltd., Cambridge, United Kingdom., Sampson AT; Lab of Viral Zoonotics, Department of Veterinary Medicine, University of Cambridge, Cambridge, United Kingdom., Einhauser S; Institute of Medical Microbiology & Hygiene, Molecular Microbiology (Virology), University of Regensburg, Regensburg, Germany., Aguinam ET; Lab of Viral Zoonotics, Department of Veterinary Medicine, University of Cambridge, Cambridge, United Kingdom., Ferrari M; DIOSynVax, Ltd., Cambridge, United Kingdom., Tonks P; Lab of Viral Zoonotics, Department of Veterinary Medicine, University of Cambridge, Cambridge, United Kingdom., Nadesalingam A; Lab of Viral Zoonotics, Department of Veterinary Medicine, University of Cambridge, Cambridge, United Kingdom., Schütz A; Institute of Medical Microbiology & Hygiene, Molecular Microbiology (Virology), University of Regensburg, Regensburg, Germany., Huang CQ; Lab of Viral Zoonotics, Department of Veterinary Medicine, University of Cambridge, Cambridge, United Kingdom., Wells DA; DIOSynVax, Ltd., Cambridge, United Kingdom., Paloniemi M; Lab of Viral Zoonotics, Department of Veterinary Medicine, University of Cambridge, Cambridge, United Kingdom., Jordan I; Applied Science & Technologies, ProBioGen AG, Berlin, Germany., Cantoni D; Viral Pseudotype Unit, Medway School of Pharmacy, The Universities of Kent and Greenwich at Medway, Chatham, United Kingdom., Peterhoff D; Institute of Medical Microbiology & Hygiene, Molecular Microbiology (Virology), University of Regensburg, Regensburg, Germany.; Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, Regensburg, Germany., Asbach B; Institute of Medical Microbiology & Hygiene, Molecular Microbiology (Virology), University of Regensburg, Regensburg, Germany., Sandig V; Applied Science & Technologies, ProBioGen AG, Berlin, Germany., Temperton N; Viral Pseudotype Unit, Medway School of Pharmacy, The Universities of Kent and Greenwich at Medway, Chatham, United Kingdom., Kinsley R; Lab of Viral Zoonotics, Department of Veterinary Medicine, University of Cambridge, Cambridge, United Kingdom.; DIOSynVax, Ltd., Cambridge, United Kingdom., Wagner R; Institute of Medical Microbiology & Hygiene, Molecular Microbiology (Virology), University of Regensburg, Regensburg, Germany.; Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, Regensburg, Germany., Heeney JL; Lab of Viral Zoonotics, Department of Veterinary Medicine, University of Cambridge, Cambridge, United Kingdom.; DIOSynVax, Ltd., Cambridge, United Kingdom.

Publikováno v: Frontiers in immunology [Front Immunol] 2023 Feb 23; Vol. 14, pp. 1118523. Date of Electronic Publication: 2023 Feb 23 (Print Publication: 2023).

Influenza A (N1-N9) and Influenza B (B/Victoria and B/Yamagata) Neuraminidase Pseudotypes as Tools for Pandemic Preparedness and Improved Influenza Vaccine Design.

Autor: da Costa KAS; Viral Pseudotype Unit, Medway School of Pharmacy, The Universities of Greenwich and Kent at Medway, Chatham ME4 4BF, UK., Del Rosario JMM; Viral Pseudotype Unit, Medway School of Pharmacy, The Universities of Greenwich and Kent at Medway, Chatham ME4 4BF, UK.; DIOSynVax, Cambridge CB3 0ES, UK., Ferrari M; DIOSynVax, Cambridge CB3 0ES, UK., Vishwanath S; Department of Veterinary Medicine, University of Cambridge, Cambridge CB3 0ES, UK., Asbach B; Institute of Medical Microbiology and Hygiene, University of Regensburg, 93053 Regensburg, Germany., Kinsley R; DIOSynVax, Cambridge CB3 0ES, UK.; Department of Veterinary Medicine, University of Cambridge, Cambridge CB3 0ES, UK., Wagner R; Institute of Medical Microbiology and Hygiene, University of Regensburg, 93053 Regensburg, Germany.; Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, 93053 Regensburg, Germany., Heeney JL; DIOSynVax, Cambridge CB3 0ES, UK.; Department of Veterinary Medicine, University of Cambridge, Cambridge CB3 0ES, UK., Carnell GW; Department of Veterinary Medicine, University of Cambridge, Cambridge CB3 0ES, UK., Temperton NJ; Viral Pseudotype Unit, Medway School of Pharmacy, The Universities of Greenwich and Kent at Medway, Chatham ME4 4BF, UK.

Publikováno v: Vaccines [Vaccines (Basel)] 2022 Sep 14; Vol. 10 (9). Date of Electronic Publication: 2022 Sep 14.

Exploiting Pan Influenza A and Pan Influenza B Pseudotype Libraries for Efficient Vaccine Antigen Selection.

Autor: Del Rosario JMM; Viral Pseudotype Unit, Medway School of Pharmacy, The Universities of Greenwich and Kent at Medway, Chatham ME4 4BF, UK.; Department of Physical Sciences and Mathematics, College of Arts and Sciences, University of the Philippines Manila, Manila 1000, Philippines.; DIOSynVax, Cambridge CB3 0ES, UK., da Costa KAS; Viral Pseudotype Unit, Medway School of Pharmacy, The Universities of Greenwich and Kent at Medway, Chatham ME4 4BF, UK., Asbach B; Institute of Medical Microbiology and Hygiene, University of Regensburg, 93053 Regensburg, Germany., Ferrara F; Viral Pseudotype Unit, Medway School of Pharmacy, The Universities of Greenwich and Kent at Medway, Chatham ME4 4BF, UK.; Vector Development and Production Laboratory, St. Jude Children's Research Hospital, Memphis, TN 38105, USA., Ferrari M; DIOSynVax, Cambridge CB3 0ES, UK.; Department of Veterinary Medicine, University of Cambridge, Cambridge CB3 0ES, UK., Wells DA; DIOSynVax, Cambridge CB3 0ES, UK.; Department of Veterinary Medicine, University of Cambridge, Cambridge CB3 0ES, UK., Mann GS; Viral Pseudotype Unit, Medway School of Pharmacy, The Universities of Greenwich and Kent at Medway, Chatham ME4 4BF, UK., Ameh VO; Department of Veterinary Public Health and Preventive Medicine, College of Veterinary Medicine, Federal University of Agriculture Makurdi, Makurdi P.M.B. 2373, Bene State, Nigeria.; Department of Veterinary Tropical Diseases, Faculty of Veterinary Science, University of Pretoria, P. Bag X04, Onderstepoort 0110, South Africa., Sabeta CT; Department of Veterinary Tropical Diseases, Faculty of Veterinary Science, University of Pretoria, P. Bag X04, Onderstepoort 0110, South Africa.; OIE Rabies Reference Laboratory, Agricultural Research Council-Onderstepoort Veterinary Research, Onderstepoort 0110, South Africa., Banyard AC; Animal and Plant Health Agency (APHA), Department of Virology, Weybridge, Surrey KT15 3NB, UK., Kinsley R; DIOSynVax, Cambridge CB3 0ES, UK.; Department of Veterinary Medicine, University of Cambridge, Cambridge CB3 0ES, UK., Scott SD; Viral Pseudotype Unit, Medway School of Pharmacy, The Universities of Greenwich and Kent at Medway, Chatham ME4 4BF, UK., Wagner R; Institute of Medical Microbiology and Hygiene, University of Regensburg, 93053 Regensburg, Germany.; Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, 93053 Regensburg, Germany., Heeney JL; DIOSynVax, Cambridge CB3 0ES, UK.; Department of Veterinary Medicine, University of Cambridge, Cambridge CB3 0ES, UK., Carnell GW; DIOSynVax, Cambridge CB3 0ES, UK.; Department of Veterinary Medicine, University of Cambridge, Cambridge CB3 0ES, UK., Temperton NJ; Viral Pseudotype Unit, Medway School of Pharmacy, The Universities of Greenwich and Kent at Medway, Chatham ME4 4BF, UK.; DIOSynVax, Cambridge CB3 0ES, UK.

Publikováno v: Vaccines [Vaccines (Basel)] 2021 Jul 05; Vol. 9 (7). Date of Electronic Publication: 2021 Jul 05.

Protection From Influenza by Intramuscular Gene Vector Delivery of a Broadly Neutralizing Nanobody Does Not Depend on Antibody Dependent Cellular Cytotoxicity.

Autor: Del Rosario JMM; Division of Biotherapeutics, National Institute for Biological Standards and Control, Potters Bar, United Kingdom.; Division of Advanced Therapies, National Institute for Biological Standards and Control, Potters Bar, United Kingdom.; Division of Infection and Immunity, University College London, London, United Kingdom.; Department of Physical Sciences and Mathematics, College of Arts and Sciences, University of the Philippines Manila, Manila, Philippines., Smith M; Division of Virology, National Institute for Biological Standards and Control, Potters Bar, United Kingdom., Zaki K; Division of Advanced Therapies, National Institute for Biological Standards and Control, Potters Bar, United Kingdom., Risley P; Division of Biotherapeutics, National Institute for Biological Standards and Control, Potters Bar, United Kingdom., Temperton N; Viral Pseudotype Unit, Medway School of Pharmacy, The Universities of Kent and Greenwich at Medway, Chatham, United Kingdom., Engelhardt OG; Division of Virology, National Institute for Biological Standards and Control, Potters Bar, United Kingdom., Collins M; Division of Advanced Therapies, National Institute for Biological Standards and Control, Potters Bar, United Kingdom.; Division of Infection and Immunity, University College London, London, United Kingdom.; Okinawa Institute of Science and Technology Graduate University, Okinawa, Japan., Takeuchi Y; Division of Advanced Therapies, National Institute for Biological Standards and Control, Potters Bar, United Kingdom.; Division of Infection and Immunity, University College London, London, United Kingdom., Hufton SE; Division of Biotherapeutics, National Institute for Biological Standards and Control, Potters Bar, United Kingdom.

Publikováno v: Frontiers in immunology [Front Immunol] 2020 May 29; Vol. 11, pp. 627. Date of Electronic Publication: 2020 May 29 (Print Publication: 2020).